Work

Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.10536

Authors: Ami Vijay Desai, Garrett M. Brodeur, Jennifer Foster, Stacey L. Berg, Ellen M. Basu, Suzanne Shusterman, Amit J. Sabnis, Margaret Macy, Janet Yoon, Karen Gauvain, Vanessa Esquibel, Edna Chow Maneval, Pratik S. Multani, Elizabeth Fox

Institutions: University of Chicago Medical Center, Comer Children's Hospital, Children's Hospital of Philadelphia, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, University of California, San Francisco, UCSF Benioff Children's Hospital, Children's Hospital Colorado, Rady Children's Hospital-San Diego, Washington University in St. Louis, Ignyta (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890777155

Cites:

Cited by: 16

Related to: 10